Chinese expert consensus on the clinical application of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease

• Published in: Chinese medical journal Vol. 137; no. 11; pp. 1264 - 1266
• Main Author: Ji Yuanyuan
• Format: Journal Article
• Language: English
• Published: China Lippincott Williams & Wilkins Ovid Technologies 05.06.2024; Lippincott Williams & Wilkins; Wolters Kluwer
• Subjects: Blood pressure; Cardiovascular disease; Clinical medicine; Clinical outcomes; Consensus; Consensus Statement; Diabetes; Drug dosages; East Asian People; Glucose; Glycemic index; Health risks; Hemodialysis; Hospitals; Humans; Hypoglycemia; Immunosuppressive agents; Infections; Kidney diseases; Kidney transplants; Medicine; Nephrology; Patients; Renal Insufficiency, Chronic - drug therapy; Sodium; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Steroids; Urogenital system; Working groups; China
• ISSN: 0366-6999; 2542-5641; 2542-5641
• DOI: 10.1097/CM9.0000000000003145

[3] As such, delaying the progression of CKD and reducing cardiovascular events are key elements in patient care. [5] The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guidelines for Diabetes Management in CKD have upgraded SGLT2 inhibitors from antihyperglycemic therapy to first-line comprehensive treatment for patients with type 2 diabetes (T2D) and CKD. Several issues remain to be resolved about the clinical application of SGLT2 inhibitors in patients with CKD: (1) The mechanism underlying the cardiorenal protection beyond the blood glucose-lowering effect; (2) The potential benefit and safety in patients with T1D, kidney transplantation, polycystic kidney disease, obesity-related kidney disease, and those taking high doses of corticosteroids or immunosuppressants; (3) More evidence-based and real-world data to support the additive cardiorenal protective effect of SGLT2 inhibitors combined with non-steroidal MRA; (4) Long-term effects of SGLT2 inhibitor on mineral bone metabolism; (5) Long term benefit and safety of SGLT2 inhibitor. Working Group Membership (Experts are listed in alphabetical order of their last name) Jianghua Chen (First Affiliated Hospital of Zhejiang University School of Medicine), Nan Chen (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine), Wei Chen (First Affiliated Hospital of Sun Yat-sen University), Leyi Gu (Renji Hospital, Shanghai Jiao Tong University School of Medicine), Chuanming Hao (Huashan Hospital, Fudan University), Fan Fan Hou (Nanfang Hospital, Southern Medical University), Yong Huo (Peking University First Hospital), Guisen Li (Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital), Xiaoying Li (Zhongshan Hospital, Fudan University), Yong Li (Huashan Hospital, Fudan University), Min Liang (Nanfang Hospital, Southern Medical University), Bicheng Liu (Zhongda Hospital, Southeast University), Huijuan Mao